These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10469679)

  • 1. What are the clinical benefits of recombinant gonadotrophins?: the development of recombinant FSH (Puregon((R))): a scientific business.
    Out HJ; Bennink HJ; de Laat WN
    Hum Reprod; 1999 Sep; 14(9):2189-90. PubMed ID: 10469679
    [No Abstract]   [Full Text] [Related]  

  • 2. What are the clinical benefits of recombinant gonadotrophins? Is Puregon a 'good' or'super' drug?
    Meniru GI
    Hum Reprod; 1999 Jun; 14(6):1409-11. PubMed ID: 10357947
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of two recombinant follicle-stimulating hormone preparations in in-vitro fertilization: a randomized clinical study.
    Tulppala M; Aho M; Tuuri T; Vilska S; Foudila T; Hakala-Ala-Pietilä T; Moilanen J; Bützow T; Kaukoranta S; Söderström-Anttila V; Siegberg R; Suikkari AM; Hovatta O
    Hum Reprod; 1999 Nov; 14(11):2709-15. PubMed ID: 10548606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle stimulating hormone (Puregon versus Metrodin) in in-vitro fertilization.
    Out HJ; Mannaerts BM; Driessen SG; Bennink HJ
    Hum Reprod; 1995 Oct; 10(10):2534-40. PubMed ID: 8567765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective randomized clinical trial comparing recombinant follicle stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-down-regulated in-vitro fertilization patients.
    Jansen CA; van Os HC; Out HJ; Coelingh Bennink HJ
    Hum Reprod; 1998 Nov; 13(11):2995-9. PubMed ID: 9853844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation.
    Harlin J; Aanesen A; Csemiczky G; Wramsby H; Fried G
    Hum Reprod; 2002 Feb; 17(2):304-9. PubMed ID: 11821268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization.
    Devroey P; Tournaye H; Van Steirteghem A; Hendrix P; Out HJ
    Hum Reprod; 1998 Mar; 13(3):565-6. PubMed ID: 9572411
    [No Abstract]   [Full Text] [Related]  

  • 8. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.
    Hoomans EH; Andersen AN; Loft A; Leerentveld RA; van Kamp AA; Zech H
    Hum Reprod; 1999 Oct; 14(10):2442-7. PubMed ID: 10527965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovulation induction with low dose alternate day recombinant follicle stimulating hormone (Puregon).
    Buckler HM; Robertson WR; Anderson A; Vickers M; Lambert A
    Hum Reprod; 1999 Dec; 14(12):2969-73. PubMed ID: 10601080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New stimulation regimens with recombinant FSH (Puregon) in in-vitro fertilization.
    Out HJ
    Eur J Obstet Gynecol Reprod Biol; 1999 Jul; 85(1):21-2. PubMed ID: 10428317
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant follicle-stimulating hormone: new biotechnology for infertility.
    Prevost RR
    Pharmacotherapy; 1998; 18(5):1001-10. PubMed ID: 9758311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative incidence of ovarian hyperstimulation syndrome following ovarian stimulation with corifollitropin alfa or recombinant FSH.
    Tarlatzis BC; Griesinger G; Leader A; Rombauts L; Ijzerman-Boon PC; Mannaerts BM
    Reprod Biomed Online; 2012 Apr; 24(4):410-9. PubMed ID: 22386594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: a prospective, randomized, assessor-blind, multicentre trial.
    Hedon B; Out HJ; Hugues JN; Camier B; Cohen J; Lopes P; Zorn JR; van der Heijden B; Coelingh Bennink HJ
    Hum Reprod; 1995 Dec; 10(12):3102-6. PubMed ID: 8822422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant follicle stimulating hormone in in-vitro fertilization treatment-clinical experience with follitropin alpha and follitropin beta.
    Harlin J; Csemiczky G; Wramsby H; Fried G
    Hum Reprod; 2000 Feb; 15(2):239-44. PubMed ID: 10655291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reproductive health--new hormonal agents to treat infertility].
    Popova B
    Akush Ginekol (Sofiia); 2002; 41 Suppl 1():23-31. PubMed ID: 12412351
    [No Abstract]   [Full Text] [Related]  

  • 17. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oestradiol and immunoreactive inhibin-like secretory patterns following controlled ovarian hyperstimulation with urinary (Metrodin) or recombinant follicle stimulating hormone (Puregon).
    Mitchell R; Buckler HM; Matson P; Lieberman B; Burger HG; Hilton B; Horne G; Dyson M; Robertson WR
    Hum Reprod; 1996 May; 11(5):962-7. PubMed ID: 8671371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What are the clinical benefits of recombinant gonadotrophins? Recombinant follicle stimulating hormone.
    Bergh C
    Hum Reprod; 1999 Jun; 14(6):1418-20. PubMed ID: 10357950
    [No Abstract]   [Full Text] [Related]  

  • 20. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles.
    Daya S; Gunby J
    Cochrane Database Syst Rev; 2000; (4):CD002810. PubMed ID: 11034767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.